Edwards Lifesciences Corporation (NYSE:EW) Stock Has Average Target Price of $100.27

Key Points

• Analysts are moderately bullish on Edwards Lifesciences, with 17 buy ratings and six holds among 23 analysts. The average 12-month price target is $100.27, versus a reported share price of $86.39.
• The company exceeded quarterly expectations, reporting $0.78 EPS versus a $0.74 estimate and $1.74 billion in revenue, up 13.6% year over year. Management guided for third-quarter 2026 EPS of $0.71–$0.77 and full-year EPS of $2.95–$3.05.
• Institutional ownership is substantial at 79.46%, led by new positions from BlackRock, Bank of New York Mellon, and Norges Bank. Meanwhile, insiders sold 5,664 shares worth approximately $511,918 over the past three months.

Shares of Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) have been given an average rating of "Moderate Buy" by the twenty-three analysts that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a hold recommendation and seventeen have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $100.27.

A number of equities analysts have issued reports on EW shares. Evercore reissued an "outperform" rating and set a $100.00 price target on shares of Edwards Lifesciences in a research report on Monday, July 6th. TD Cowen reaffirmed a "buy" rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. JPMorgan Chase & Co. increased their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a research note on Friday, July 24th. BTIG Research reissued a "buy" rating and set a $110.00 target price on shares of Edwards Lifesciences in a report on Friday, September 11th. Finally, UBS Group began coverage on shares of Edwards Lifesciences in a research report on Tuesday, July 28th. They set a "buy" rating and a $110.00 target price for the company.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Annette Brüls sold 2,644 shares of Edwards Lifesciences stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares in the company, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Andrew M. Dahl sold 544 shares of the business's stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the completion of the transaction, the senior vice president directly owned 14,868 shares of the company's stock, valued at approximately $1,353,880.08. This trade represents a 3.53% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 5,664 shares of company stock valued at $511,918. Company insiders own 0.31% of the company's stock.

Institutional Investors Weigh In On Edwards Lifesciences

Several hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in Edwards Lifesciences during the second quarter valued at $5,318,092,000. Bank of New York Mellon Corp acquired a new position in shares of Edwards Lifesciences in the second quarter worth about $1,274,082,000. Norges Bank purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $803,686,000. Bank of America Corp DE purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $605,397,000. Finally, Deutsche Bank AG purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $516,552,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Up 0.8%

Edwards Lifesciences stock opened at $86.39 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The business's 50-day simple moving average is $88.43 and its two-hundred day simple moving average is $85.99. The company has a market cap of $49.75 billion, a PE ratio of 49.65, a PEG ratio of 2.25 and a beta of 0.85. Edwards Lifesciences has a fifty-two week low of $72.30 and a fifty-two week high of $96.29.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to analysts' expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company's revenue for the quarter was up 13.6% compared to the same quarter last year. During the same period last year, the business posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts anticipate that Edwards Lifesciences will post 3 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation NYSE: EW is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company's portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.